Home Novocure

Novocure

Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma

4/17/18: Final STELLAR data exceeded the results of the interim analysis for all efficacy endpoints. Novocure plans to submit a Humanitarian Device Exemption application to the FDA for approval

Novocure’s Optune Now Available at More Than 600 Cancer Treatment Centers in the U.S.

Optune is Novocure’s wearable, portable, FDA-approved Tumor Treating Fields (TTFields) delivery system for the treatment of GBM.

First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma

Novocure™ (NASDAQ: NVCR) announced today that the first patient has been enrolled in the RTOG Foundation’s phase...

Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma

“We believe that treatment with TTFIelds affects fundamental aspects of cell division and may have broad applicability...

Martin J. Madden Joins Novocure Board of Directors

The company said that Mr. Madden recently retired after a 30-year career in medical device innovation at...

Novocure Reports First Quarter 2017 Financial Results and Provides Company Update

More than 1,260 active patients at March 31, 2017, an increase of 59 percent from March 31,...

Novocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston

Company reports that the data suggest combined modality treatment with TTFields and triplet combination chemotherapy may extend...